Scarica l'app Stockscreener
4.11
0.98%
0.04
Dopo l'orario di chiusura:
4.23
0.12
+2.92%
Precedente Chiudi:
$4.07
Aprire:
$4.07
Volume 24 ore:
107.55K
Relative Volume:
0.37
Capitalizzazione di mercato:
$12.66M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.2687
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
+24.17%
1M Prestazione:
-43.31%
6M Prestazione:
-68.47%
1 anno Prestazione:
-90.76%
Intervallo 1D:
$4.05
$4.34
Intervallo di 1 settimana:
$3.25
$4.34
Portata 52W:
$3.13
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Confronta MBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.11 | 12.53M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-12 | Downgrade | Maxim Group | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Buy Signal: Why Moleculin Biotech Inc. stock could rally in 20252025 Stock Rankings & Weekly Chart Analysis and Trade Guides - ulpravda.ru
What technical charts say about Moleculin Biotech Inc. stockGap Up & Reliable Breakout Stock Forecasts - ulpravda.ru
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why retail investors favor Moleculin Biotech Inc. stockEarnings Miss Alerts & Free Fast Track Wealth Growth - ulpravda.ru
Why Moleculin Biotech Inc. stock is considered a top pickMarket Insider Reports & Budget Friendly Trading Strategies - ulpravda.ru
Moleculin Biotech regains Nasdaq listing compliance - MarketScreener
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView — Track All Markets
Why Moleculin Biotech Inc. stock remains a top recommendation2026 world cup usa national team round of 32 midfield engines counter attacking tactical prediction breakdown - ulpravda.ru
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million - Investing.com Nigeria
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million By Investing.com - Investing.com South Africa
Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance - TipRanks
Moleculin Biotech Signs Warrant Amendment Agreements With Holders of Series E, F and G Warrants - TradingView — Track All Markets
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Will Moleculin Biotech Inc. stock rally after Fed decisions2025 Volatility Report & Long Hold Capital Preservation Tips - Улправда
Will Moleculin Biotech Inc. stock split attract more investorsMarket Performance Report & Safe Capital Growth Plans - Улправда
Moleculin Biotech Earnings Notes - Trefis
Moleculin Biotech (LTS:0K2H) EV-to-OCF : -0.07 (As of Dec. 19, 2025) - GuruFocus
How risky is Moleculin Biotech Inc. (MOL) stock compared to peersJuly 2025 Spike Watch & Target Return Focused Picks - DonanımHaber
Why Moleculin Biotech Inc. (MOL) stock is listed among top recommendationsJuly 2025 PreEarnings & Technical Pattern Based Signals - DonanımHaber
Earnings Report: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Улправда
Market Review: Why Moleculin Biotech Inc. stock could rally in 2025July 2025 Snapshot & Fast Gain Swing Alerts - DonanımHaber
Why Moleculin Biotech Inc. stock could rally in 2025Global Markets & Verified Momentum Stock Watchlist - DonanımHaber
Aug Wrap: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Why Moleculin Biotech Inc. stock is popular among millennialsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
Why hedge funds are buying Moleculin Biotech Inc. stockTrade Risk Summary & Accurate Trade Setup Notifications - ulpravda.ru
Moleculin Biotech reports positive phase 1 trial results - MSN
Moleculin Biotech stock falls after pediatric brain tumor trial results By Investing.com - Investing.com Australia
Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade
Moleculin’s brain cancer drug shows promise in pediatric trial By Investing.com - Investing.com Nigeria
Moleculin Shares Drop 17% Despite Positive Phase 1 WP1066 Data In Pediatric Brain Tumors - Nasdaq
Moleculin Biotech Prepares for 1-for-25 Reverse Split Amidst Clinical Advancements - timothysykes.com
Moleculin Biotech regains Nasdaq compliance - MSN
Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq
Moleculin announces positive phase 1 data for WP1066 in pediatric brain tumors - marketscreener.com
Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com
Moleculin’s brain cancer drug shows promise in pediatric trial - Investing.com
Moleculin Biotech stock falls after pediatric brain tumor trial results - Investing.com
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):